Dr. Colin Minchom has been appointed vice president of Hovione’s Particle Design Business Unit. Dr. Minchom joins the company from Patheon, where he served as vice president of Pharmaceutical Development Services for North America. Based in East Windsor, NJ, Dr. Minchom will report to Guy Villax, Hovione’s chief executive officer.
 
“We are very pleased to welcome Dr. Minchom to Hovione. He is an excellent addition to our management team in an area of critical importance to our customers. Dr. Minchom is responsible for innovating Hovione’s Pharmaceutical Particle Design offerings to meet the development and commercial supply needs of the formulator with poorly bioavailable or otherwise challenging molecules,” said Mr. Villax.
 
Dr. Minchom has 29 years of experience in the process, science and global regulation of drug development with emphasis on dosage forms and drug delivery. Prior to this role at Patheon Dr. Minchom was head of Pharmaceutical Sciences at Cerebrus Ltd., a UK pharmaceutical company. He also held positions of increasing responsibility at Eli Lilly and E.R. Squibb in formulation and product development, project management and product management.